Agilent Technologies has a company-confirmed earnings report dropping after the close on August 26, and every operating lever heading into that date is pointing the same direction. Here is what retirement-focused investors need to understand before the bell rings.

Former General Electric and Thermo Fisher Scientific counsel Jonas Svedlund will oversee the carrier’s legal and compliance functions.

BIO's 19.1% monthly rally is backed by digital PCR gains and steadier diagnostics, but weak Life Science demand and a rich valuation loom.

ABT's Medical Devices growth is fueled by electrophysiology, expanding CGM adoption and a cardiovascular pipeline extending into 2029 and beyond.

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how research tools & consumables stocks fared in Q2, starting with Thermo Fisher (NYSE:TMO).

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.

Thermo Fisher Scientific has underperformed the broader market over the past year, yet analysts remain highly bullish about the stock’s prospects.

PTC Therapeutics (NASDAQ:PTCT) plans to acquire the ST-920 Fabry disease gene therapy asset through a competitive bankruptcy auction, positioning the company to add a potential one-time treatment to its rare disease portfolio while using its existing global commercial and regulatory infrastructure.

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

European private equity firm Astorg will run the business as an independent diagnostics company, led by former PerkinElmer CEO Dirk Bontridder.

LivaNova PLC recently reported second-quarter 2026 results showing sales rising to US$390.59 million and net income climbing to US$108.57 million, alongside higher earnings per share versus a year earlier. On the back of this performance, the company raised its 2026 constant-currency revenue growth guidance to a range of 8% to 9% and secured a long-term oxygenator supply agreement with Thermo Fisher Scientific to support manufacturing expansion. Now we’ll examine how the raised 2026 growth...

LivaNova (LIVN) raised its full year 2026 revenue and earnings guidance after reporting record quarterly revenue and significantly higher profitability, supported by demand for its Essenz heart-lung machine and a new supply agreement with Thermo Fisher Scientific. See our latest analysis for LivaNova. LivaNova's recent guidance lift comes after a strong run in the share price, with a 90 day share price return of 12.71% and a year to date share price return of 33.21%. The 1 year total...

Arcturus Therapeutics (NASDAQ:ARCT) is positioning its mRNA platform around two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, while its vaccine business is intended to help support therapeutic development, President and CEO Joseph Payne said during a Cana

Thermo Fisher Scientific (NYSE:TMO) mostly sells the instruments and supplies that let other companies do science, not the treatments themselves. So when the company said on July 29 that it had launched the PPD CorEvitas Vitiligo Registry on July 14, to track how patients with nonsegmental vitiligo respond to treatment, it pointed to a quieter […]

Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 1% and th

In late July 2026, Thermo Fisher Scientific used the ADLM conference in Anaheim to highlight new FDA-cleared diagnostic platforms, including the EXENT Solution for multiple myeloma and EliA CTD 13 Screen for systemic autoimmune connective tissue diseases, alongside expanded digital and quality-control offerings for clinical laboratories. By pairing these regulatory milestones with integrated software such as LabLink360 and broad biomarker portfolios like B·R·A·H·M·S, Thermo Fisher is...

Healthcare stocks were higher Monday afternoon, with the NYSE Healthcare Index up 0.9% and the State

AVAH, FDS and SHOP lead Zacks' recent standouts, with several picks posting strong gains versus the S&P 500.

By Rishika Sadam HYDERABAD, Aug 10 (Reuters) - Thermo Fisher Scientific is eyeing a 15%-20% increase in its customer base in India over the next five years, betting on the growing biopharma research

Thermo Fisher Scientific Inc. (NYSE:TMO) and Danaher Corporation (NYSE:DHR) are two of the world’s largest life sciences tools companies, making them natural competitors for investors looking to capitalize on a recovery in pharmaceutical and biotechnology research spending. Both companies delivered better-than-expected second-quarter results, but while Thermo Fisher (NYSE:TMO) raised guidance on broad-based demand improvement, Danaher’s […]

LH shares surged 14% in a month as stronger earnings, margin gains and growth collide with a valuation above the company's five-year median.

Becton Dickinson (BDX) raised its full-year earnings guidance as the medical device maker's third-qu

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

TMO lifted its 2026 outlook after Q2 topped estimates, driven by stronger demand, acquisitions and margin gains. Can the momentum continue?

Examine the evolution of Thermo Fisher's (TMO) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

Researchers found that widely used lab machines produced digital DNA files that are vulnerable to tampering.

Microsoft rides AI, Copilot and Azure growth, but can expanding cloud demand and capacity challenges shape its next phase?

Thermo Fisher Scientific Inc. (NYSE:TMO) recently announced strong fiscal Q2 2026 results, with revenue growing 10% to $11.99 billion, GAAP diluted EPS rising 9% to $4.68, and adjusted EPS growing 13% to $6.03. The results prompted several analysts to raise their price targets, but after the post-earnings rally, investors must decide whether the recovery story […]

TMO is expanding bioproduction, AI tools and clinical data capabilities, but execution will be key as competition intensifies.

Thermo Fisher Scientific (TMO) is back in focus after reporting second quarter results that exceeded market expectations, supported by broad-based demand and fresh regulatory clearances across its diagnostics portfolio. See our latest analysis for Thermo Fisher Scientific. Thermo Fisher Scientific’s recent earnings beat and steady flow of product clearances have coincided with a 30-day share price return of 15.04% and a 22.92% 90-day share price return. The 1-year total shareholder return of...

Organic revenue still fell, yet a segment returning to growth and a raised outlook were enough to reprice the stock in a single session.

Thermo Fisher’s second quarter saw a notable uptick in end-market activity, propelling results above Wall Street’s expectations and leading to a positive market reaction. Management pointed to stronger demand across pharmaceutical, biotech, industrial, and diagnostics markets, with CEO Marc Casper highlighting “broad-based momentum” and “excellent execution” in core segments such as Bioproduction and Clinical Research. Newly launched high-end instruments and AI-powered software were key contribu

Jefferies just named five U.S. dividend stocks to its exclusive Global Best Ideas list, and with the S&P 500 stretched to historically expensive valuations, the case for these high-conviction picks has never been more urgent.

MNST, CRS and USIO highlight Zacks strategies that outperformed amid a volatile market.

Thermo Fisher Scientific's (TMO) broad-based improvement in Q2 is not enough to "meaningfully" chang

Life sciences company Thermo Fisher (NYSE:TMO) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 10.5% year on year to $11.99 billion. Its non-GAAP profit of $6.03 per share was 5.6% above analysts’ consensus estimates.

Companies in The News Are: TMO, TSLA, UNP, CSX

Moby summary of Thermo Fisher Scientific Inc.'s Q2 2026 earnings call

Danaher's latest earnings call saw analysts repeatedly test one sore spot in an otherwise solid quarter, and management's answers reveal the key risk for investors now.

Thermo’s Q2 performance was driven by its laboratory products and biopharma services business with profits around $6.69bn equating to a 12% uptick YoY.

Thermo Fisher Scientific (NYSE:TMO) has been selected by ImmuPharma as the key drug product and contract development manufacturer for its Kapiglucagon diabetes treatment program. The partnership covers development and manufacturing support for Kapiglucagon, an experimental therapy aimed at addressing diabetes. This agreement adds a new project to Thermo Fisher Scientific’s pharmaceutical services portfolio, focused on complex drug development work. For investors tracking Thermo Fisher...

Thermo Fisher Scientific Inc. (NYSE:TMO) saw its share prices increase by 8.71 percent on Thursday to close at $572.32 apiece, as investors took heart from the strong earnings performance and a series of price target upgrades for its stock. In the second quarter of the year, the company grew its net income by 7 percent […]

Thermo Fisher Scientific (NYSE:TMO) reported stronger-than-expected second-quarter 2026 results and raised its full-year outlook, citing improving customer activity across end markets, broad-based growth and contributions from recent acquisitions. Chairman and Chief Executive Officer Marc Casper sa

Organic revenue beat guidance at 5% as pharma and biotech activity strengthened.

Thermo Fisher Scientific Inc (TMO) reports a 10% revenue increase and raises full-year guidance, driven by innovation and strategic acquisitions.

Shares of life sciences company Thermo Fisher (NYSE:TMO) jumped 9.7% in the afternoon session after the company reported strong second-quarter earnings that beat Wall Street's estimates for both profit and revenue. For the quarter, the company reported adjusted earnings per share of $6.03, topping expectations of $5.71. Revenue came in at $11.99 billion, a 10.5% year-over-year increase that surpassed Wall Street's forecasts of $11.72 billion. Organic revenue also grew by 5% year on year. Further

Thermo Fisher beats Q2 earnings and revenue estimates as organic growth and stronger customer activity lift results, sending shares higher in pre-market trading.

Thermo Fisher stock led a medtech rebound Thursday, easing investors' fears of continued malaise for the medical research and tools realm.

Although the revenue and EPS for Thermo Fisher (TMO) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock